Regardless of the sequential decrease in Current Liabilities, during the third quarter 2026, Quick Ratio deteriorated to 13.58 above company average Quick Ratio.

Within Medical Laboratories industry 2 other companies have achieved higher Quick Ratio than Aclarion Inc in third quarter 2026. While Quick Ratio total ranking has improved so far during the Q3 2026 to 248, from total ranking in the second quarter 2026 at 402.

Explain Quick Ratio?
How much Cash & cash equivalents ACON�s has?
What are ACON�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/ACON/financial-strength

https://api.csimarket.com/api/v1/companies/ACON/fundamentals

https://api.csimarket.com/api/v1/companies/ACON/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

ACON Quick Ratio	(Sep 30 2026) Q3	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3
Y / Y Current Liabilities Change	49.28 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	25.1 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	13.58	Subscribe	Subscribe	Subscribe	Subscribe
ACON's Total Ranking	# 248	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	-0.58 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	-12.88 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio third quarter 2026 Company Ranking
Within:	No.
Medical Laboratories Industry	# 3
Healthcare Sector	# 115
Overall Market	# 351

Quick Ratio Statistics
High	Average	Low
22.73	6.82	0.01
(Jun 30 2025)		(Mar 31 2022)

Financial Statements
Aclarion Inc 's Current Liabilities	$ 1 Millions	Visit ACON's Balance sheet
Aclarion Inc 's Cash & cash equivalent	$ 14 Millions	Visit ACON's Balance sheet
Source of ACON's Sales		Visit ACON's Sales by Geography

Cumulative Aclarion Inc 's Quick Ratio

ACON's Quick Ratio for the trailling 12 Months

ACON Quick Ratio	(Sep 30 2026) 12 Months	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	25.74 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	56.19 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	15.69	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 2966	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	9.65 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	4.85 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to ACON Financial Strength Comparisons >> Go to Compare ACON Quick Ratio to its Competitors

News about Aclarion Inc Quick Ratio

Aclarion Announces Pricing of $3.0 Million Public Offering Amidst Financial Concerns

Aclarion, Inc. Announces Pricing of Public Offering Amidst Financial Concerns
BROOMFIELD, CO Aclarion, Inc. (Nasdaq: ACON, ACONW), a healthcare technology company specializing in leveraging biomarkers and proprietary augmented intelligence algorithms, recently announced the pricing of its public offering of 5,175,000 units. Each unit consists of one share of common stock (or one pre-funded warrant in lieu thereof), and two common warrants, with each common warrant allowing the purchase of one share of common stock. The public offering price has been set at $0.58 per unit.
The company s decision to proceed with a public offering comes at a crucial time as Aclarion faces challenges related to its financial health. In the third quarter of 2023, the company witnessed an increase in current liabilities, causing its Quick Ratio to fall to a concerning 0.07, well below the Aclarion Inc average Quick Ratio. Comparatively, 38 other companies within the industry have reported higher Quick Ratios during the same period.

On the trailing twelve months basis Due to decrease in Current Liabilities in the Q3 2026 to $1.04 millions, cumulative Quick Ratio decreased to 15.69 above the ACON average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Medical Laboratories industry 29 other companies have achieved higher Quick Ratio than Aclarion Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 2897 to 2966.

Explain Quick Ratio?
How much Cash & cash equivalents ACON�s has?
What are ACON�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Medical Laboratories Industry	# 30
Healthcare Sector	# 808
Within the Market	# 2966

trailing twelve months Quick Ratio Statistics
High	Average	Low
18.19	5.79	0.27
(Dec 31 2025)		(Dec 31 2023)

Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Medical Laboratories Industry	Quick Ratio	Sep 30 2026 MRQ Cash & cash equivalent	Sep 30 2026 MRQ Current Liabilities
Aclarion Inc	13.58	$ 14.188 Millions	$ 1.044 Millions
Celcuity Inc	12.38	$ 642.703 Millions	$ 51.925 Millions
Miragen Therapeutics Inc	11.70	$ 955.206 Millions	$ 81.673 Millions
Billiontoone Inc	9.26	$ 561.512 Millions	$ 60.637 Millions
Maxcyte inc	6.36	$ 101.280 Millions	$ 15.916 Millions
Personalis Inc	5.17	$ 254.841 Millions	$ 49.274 Millions
Veracyte Inc	4.40	$ 370.532 Millions	$ 84.209 Millions
Castle Biosciences Inc	4.11	$ 277.665 Millions	$ 67.612 Millions
Fulgent Genetics Inc	4.07	$ 292.739 Millions	$ 71.877 Millions
Omniab Inc	3.81	$ 64.210 Millions	$ 16.853 Millions
Guardant Health Inc	2.75	$ 1,026.848 Millions	$ 373.165 Millions

Date modified: 2026-11-06T13:01:29+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.